Cemiplimab (Libtayo) is a human monoclonal antibody injected intravenously that targets programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands PD-1 and PD-L2. Cemiplimab blocks T-cell inactivation and boosts the immune systems antitumor response.
Reinheit:
>99%, Endotoxin < 2 EU/mg
CAS Nummer:
[1801342-60-8]
Target-Kategorie:
PD-1/PD-L1
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
